Last updated: February 20, 2026
What is the drug identified by NDC 51079-0753?
NDC 51079-0753 refers to Nucala (mepolizumab), a monoclonal antibody approved for severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic granulomatosis with polyangiitis (EGPA).
Market Size and Demand Drivers
Therapeutic Indication Adoption:
- Asthma: Approximately 25 million Americans diagnosed with asthma, with an estimated 5-10% classified as severe eosinophilic asthma.
- Chronic Rhinosinusitis with Nasal Polyps: Affects roughly 2-4% of the U.S. population, with eosinophilic subtype comprising about 50%.
- Eosinophilic Granulomatosis with Polyangiitis (EGPA): Less common, affecting 0.5-4 per million annually.
Market Penetration:
- Globally, the severe eosinophilic asthma segment contributes to a $4 billion market in 2023, projected to grow at a CAGR of 12% through 2028.
- U.S. asthma market (~$1.2 billion in 2022) sees about 15-20% of patients qualifying for biologic therapies like mepolizumab.
- The nasal polyps indication adds a new revenue channel, expanding the total addressable market.
Competitive Landscape:
- Major competitors include Fasenra (benralizumab), Cinqair (reslizumab), and Dupixent (dupilumab) for nasal polyps.
- Price positioning and formulary access influence market share, with biosimilar development potential in the future.
Price Trends and Projection Factors
Current Pricing Dynamics:
- The average wholesale price (AWP) for mepolizumab is approximately $32,500 per year per patient, based on manufacturer disclosures and standard pharmacy reimbursement data.
- Medicare and private payers negotiate discounts, often resulting in net prices of around $22,000–$26,000.
Pricing Strategies:
- The manufacturer (GlaxoSmithKline) maintains a list price reflecting the high-value, chronic treatment status.
- Reimbursement and insurance policies heavily influence actual patient out-of-pocket costs and access levels.
Factors Affecting Future Pricing:
- Market Competition: Entry of biosimilars could pressure prices downward by 20-30% within 3-5 years.
- Regulatory Changes: Potential shifts in pricing regulations or value-based reimbursement models could modify pricing strategies.
- Demand Growth: Increased awareness and diagnosis of eosinophilic conditions expand the eligible patient pool.
- Manufacturing Costs: Improvements in production efficiency may reduce costs marginally, influencing pricing flexibility.
Projected Price Trends (2023-2028):
| Year |
Estimated Average Price (per patient/year) |
Key Drivers |
| 2023 |
$32,500 |
Stable list price with moderate discounts |
| 2024 |
$31,600 |
Increased biosimilar competition begins |
| 2025 |
$30,000 |
Enhanced payer negotiations, generic entry |
| 2026 |
$28,000 |
Biosimilar market penetration, cost reductions |
| 2027 |
$27,000 |
Market saturation, policy influences |
| 2028 |
$26,000 |
Potential biosimilar dominance |
External Influences and Policy Impact
Policymakers and payers focus on controlling escalating biologic costs. Price negotiations and outcome-based contracts could further reduce net prices. The uptake of biosimilars remains uncertain but is a significant factor in downward pricing pressures.
Summary
Nucala (mepolizumab) faces a growing market driven by expanding indications and unmet needs within severe eosinophilic conditions. Current list prices hover around $32,500, with projections indicating gradual decreases driven by biosimilar competition and evolving reimbursement policies. Overall, the market size is expected to expand at a CAGR of approximately 12%, with prices declining modestly over the next five years.
Key Takeaways
- The biologic targets a high-value, growing niche within asthma and sinusitis.
- Pricing reflects high development and manufacturing costs, with a current list price near $32,500 annually.
- Biosimilar entry could reduce prices by 20-30% over the next 3-5 years.
- Market growth is supported by increased diagnosis and approval in additional indications.
- Reimbursement policies will heavily influence net pricing and patient access.
Frequently Asked Questions
Q1: What factors most influence mepolizumab's pricing?
A1: Competition from biosimilars, payer negotiations, demand growth, and regulatory changes.
Q2: How significant could biosimilar competition be?
A2: Biosimilars could enter in 3-5 years, potentially reducing prices by 20-30%.
Q3: What is the current market size for mepolizumab?
A3: The global market is approximately $4 billion for eosinophilic asthma and related indications.
Q4: How does insurance coverage impact actual patient costs?
A4: Negotiated discounts and formulary positioning determine patient out-of-pocket expenses, influencing treatment accessibility.
Q5: Are new indications expected to expand the market?
A5: Yes, expanding approvals and increasing diagnosis rates will likely enlarge the treated population.
References
[1] IQVIA. (2022). The US Market for Biologics.
[2] GSK. (2023). Nucala (mepolizumab) prescribing information.
[3] Evaluate Pharma. (2023). Biologic market projections and biosimilar penetration estimates.
